12 May 2016. Prous Institute will be exhibiting at the 17th Drug Discovery Summit and 4th Discovery Chemistry & Drug Design Congress, 13-14 June 2016.
At the exhibition, the latest version of our predictive analytics platform, Symmetry, and Global Mechanism of Action (GMoA) pharmacological profiling tool will be presented.
In a single predictive model, Symmetry GMoA screens over 1,000 mechanisms of action (MoAs) – including 250 MoAs linked to adverse events – to identify the probable molecular targets and functional activity (agonists, antagonists, allosteric modulators, etc.) of compounds, in addition to binding. Its expertly curated and updated training set of close to 1 million compounds is uniquely derived from the analysis of patents, journal articles, congresses and public databases and covers diverse target families including GPCRs, kinases and other enzymes, ion channels, nuclear hormone receptors, transporters and protein-protein interactions.
Symmetry GMoA is used by discovery scientists for hypothesis generation and findings support drug design, lead optimization and prioritization of candidates. GMoA is also used to elucidate the underlying mechanisms behind phenotypic assay results, evaluate compounds acting simultaneously on multiple disease-relevant targets, detect off-target liabilities early in drug discovery and uncover the full mechanistic profile to anticipate potential therapeutic uses of chemical series before patent submission.
At our stand, we will present more information including recent case studies assessing pharmacological activity of different drug classes and their comparison with experimental results across a range of targets.
For further information or to schedule a meeting during the conference, please contact firstname.lastname@example.org.